Weyburn has no new COVID cases as of May 30, and active cases in the city area are down to three, with 112 active cases in the southeast region. There are 171 new cases of COVID-19 to report in Saskatchewan on May 30, bringing the provincial total to 46,635 cases.
One new death is reported today in the 80+ age group from the Southeast zone.
The new cases are located in the following zones: Far North West, 7; Far North East, 2; Northwest, 12; North Central, 17; Northeast, 3; Saskatoon, 70; Central West, 3; Central East, 6; Regina, 19; Southwest, 4; South Central, 10; and Southeast, 17. One new case is pending residence information.
There are 109 people in hospital, the lowest total in hospital since November 28, 2020. Eighty-four people are receiving inpatient care: North West, 5; North Central, 5; North East, 2; Saskatoon, 35; Central East, 3; Regina, 30; South West, 2; South Central, 1; and South East, 1. Twenty-five people are in intensive care: North West, 1; North Central, 4; Saskatoon, 11; Central East, 1; and Regina, 8. There were 145 new recoveries as of May 30.
The seven-day average of new COVID-19 case number is 137 (11.1 per 100,000).
There were 2,241 COVID-19 tests processed in Saskatchewan on May 29, including 142 tests in the southeast region.
An additional 11,061 doses of COVID-19 vaccine have been given in Saskatchewan, including 572 doses in the southeast region, bringing the total number of vaccines administered in the province to 717,609.
Seventy-seven per cent of those over the age of 40 have received their first dose, 71 per cent of those 30+ have received their first dose, and 66 per cent of those 18+ have received their first dose.
Second dose vaccinations are open to residents 70+ or anyone who received their first dose before March 15, 2021. Individuals diagnosed with or being treated for cancer and those who have received solid organ transplants will receive a letter of eligibility in the mail that will allow them priority access to a second dose.
Eligibility to book for second doses is based on age or date of first dose. Residents who meet at least one of these criteria will be eligible for their second dose.
At this time AstraZeneca is only available for second doses for individuals who received AstraZeneca for their first dose and who are over the age of 85 or cancer patients, solid organ transplant patients, or patients receiving treatment with Rituximab and Ocrelizumab, who received a letter. These individuals will be contacted for an appointment.
Guidance on the administration of AstraZeneca second doses for the general population will be provided prior to the recommended 12-week interval between doses, which begins the second week of June.
